Literature DB >> 26237105

Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.

Joshua W Wang1,2, Ken Matsui3,2, Yuanji Pan3, Kihyuck Kwak1, Shiwen Peng4, Troy Kemp3, Ligia Pinto3, Richard B S Roden1,4,5.   

Abstract

Immunization with Human Papillomavirus (HPV) L1 virus-like particles or L2 capsid protein elicits neutralizing antibodies that mediate protection. A high-throughput and sensitive in vitro neutralization assay is therefore valuable for prophylactic HPV vaccine studies. Over several hours during infection of the genital tract, virions take on a distinct intermediate conformation, including a required furin cleavage of L2 at its N-terminus. This intermediate is an important target for neutralization by L2-specific antibody, but it is very transiently exposed during in vitro infection of most cell lines resulting in insensitive measurement for L2, but not L1-specific neutralizing antibodies. To model this intermediate, we describe a protocol to generate furin-cleaved HPV pseudovirions (fc-PsV), which deliver an encapsidated reporter plasmid to facilitate infectivity measurements. We also describe a protocol for use of fc-PsV in a high-throughput in vitro neutralization assay for the sensitive measurement of both L1 and L2-specific neutralizing antibodies.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  HPV L2; HPV neutralization assay; antibody; furin-cleavage; human papillomavirus; papillomavirus

Mesh:

Substances:

Year:  2015        PMID: 26237105      PMCID: PMC4533841          DOI: 10.1002/9780471729259.mc14b05s38

Source DB:  PubMed          Journal:  Curr Protoc Microbiol


  31 in total

1.  Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage.

Authors:  E D Anderson; J K VanSlyke; C D Thulin; F Jean; G Thomas
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

2.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

Authors:  Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil D Christensen; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

3.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

4.  A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Authors:  Ratish Gambhira; Balasubramanyam Karanam; Subhashini Jagu; Jeffrey N Roberts; Christopher B Buck; Ioannis Bossis; Hannah Alphs; Timothy Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.

Authors:  Troy J Kemp; Allan Hildesheim; Roni T Falk; John T Schiller; Douglas R Lowy; Ana Cecilia Rodriguez; Ligia A Pinto
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

6.  Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Authors:  Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

7.  Production of papillomavirus-based gene transfer vectors.

Authors:  Christopher B Buck; Cynthia D Thompson
Journal:  Curr Protoc Cell Biol       Date:  2007-12

8.  Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.

Authors:  Patricia M Day; Ratish Gambhira; Richard B S Roden; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

9.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

10.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more
  8 in total

1.  Phosphorylation of the Human Papillomavirus E2 Protein at Tyrosine 138 Regulates Episomal Replication.

Authors:  Leny Jose; Elliot J Androphy; Marsha DeSmet
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

Review 2.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

3.  Pyk2 Regulates Human Papillomavirus Replication by Tyrosine Phosphorylation of the E2 Protein.

Authors:  Leny Jose; Marsha DeSmet; Elliot J Androphy
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

4.  Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Authors:  Sarah M Valencia; Athina Zacharia; Alexander Marin; Rebecca L Matthews; Chia-Kuei Wu; Breana Myers; Chelsea Sanders; Simone Difilippantonio; Reinhard Kirnbauer; Richard B Roden; Ligia A Pinto; Robert H Shoemaker; Alexander K Andrianov; Jason D Marshall
Journal:  Hum Vaccin Immunother       Date:  2021-02-11       Impact factor: 3.452

5.  Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.

Authors:  Melinda Ahmels; Filipe C Mariz; Ilona Braspenning-Wesch; Sonja Stephan; Bettina Huber; Gabriele Schmidt; Rui Cao; Martin Müller; Reinhard Kirnbauer; Frank Rösl; Daniel Hasche
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

6.  A broadly protective vaccine against cutaneous human papillomaviruses.

Authors:  Filipe Colaco Mariz; Kathrin Balz; Manuela Dittrich; Yueru Zhang; Fan Yang; Xueer Zhao; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal:  NPJ Vaccines       Date:  2022-10-10       Impact factor: 9.399

7.  Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions.

Authors:  Georgia Schäfer; Lisa M Graham; Dirk M Lang; Melissa J Blumenthal; Martina Bergant Marušič; Arieh A Katz
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering.

Authors:  Joseph G Skeate; Wouter H Segerink; Mauricio D Garcia; Daniel J Fernandez; Ruben Prins; Kim P Lühen; Féline O Voss; Diane M Da Silva; W Martin Kast
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.